Search results
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
Jennifer Lopez cancels This Is Me…Now The Tour, including Acrisure Arena stop
The Desert Sun· 3 days agoSinger Jennifer Lopez announced Friday that she is canceling her upcoming tour, This Is Me…Now The...
One of AbbVie's post-Humira hopefuls gets closer to clearing hurdle in Europe
Crain s Chicago Business· 3 days agoThe EMA Committee for Medicinal Products for Human Use is recommending approval of the drug for the treatment of adults with moderately to severely active ulcerative colitis ...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following...
Digital Journal· 8 hours ago“Bizaxofusp represents a promising novel approach for targeted delivery of a potent therapeutic payload in rGBM, a uniformly fatal form of brain cancer that does not have an approved standard ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Quincy Herald-Whig· 3 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 3 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA ...
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with...
The Parsons Sun· 4 days agoThe positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely
CAVA Group sits at all-time high ahead of Q1 earnings
The Forex Market· 6 days agoCAVA Group is a Mediterranean food chain that is growing its location base at breakneck speed. CAVA...
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative...
The Longview News-Journal· 6 days agoNew safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 2 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related